Wednesday, May 6, 2026
Insulet beats, ups revenue outlook
Insulet beats Q1 2026 estimates with EPS $1.42, revenue $761.7 million, raises 2026 constant-currency revenue growth outlook to 21%–23%
- Zacks consensus had projected Q1 EPS of $1.14 and revenue of $728.2 million, both exceeded by results.
- Insulet now expects 2026 constant-currency revenue growth of 21%–23%, up from its prior full-year guidance range.
- Full-year 2026 outlook includes higher Omnipod revenue expectations and improved EPS guidance versus the company’s previously disclosed targets.
- Updated revenue and guidance figures were disclosed in Insulet’s latest SEC filing for Q1 2026 results.
Medline beats, ups guidance
Medline posts Q1 adjusted EPS $0.33 on revenue $7.35B, beating profit and sales expectations, raises 2026 organic growth guidance
- Q1 2026 net sales increased 10.7% to $7.4B, while net income declined 25.8% to $239M
- Raised full-year 2026 organic sales growth guidance range to 8.5%–9.5%.
- Maintained full-year 2026 Adjusted EBITDA outlook while updating organic sales growth guidance.
Bioventus tops Q1 2026 expectations, raises guidance
Bioventus tops Q1 2026 expectations, raises full-year adjusted EPS guidance to $0.75–$0.79 and cash from operations outlook
- Q1 2026 net income was $3.1 million on revenue of $132.1 million.
- Management reaffirmed full-year revenue outlook while raising adjusted EPS and cash from operations guidance.
Subscribe to:
Posts (Atom)